Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients

BACKGROUND: Gefitinib, a small molecule tyrosine kinase inhibitor of the Epidermal Growth Factor Receptor (EGFR), has shown limited efficacy in the treatment of lung cancer. Recognized clinical predictors of response to this drug, specifically female, non-smoker, Asian descent, and adenocarcinoma, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugh, Trevor J, Bebb, Gwyn, Barclay, Lorena, Sutcliffe, Margaret, Fee, John, Salski, Chris, O'Connor, Robert, Ho, Cheryl, Murray, Nevin, Melosky, Barbara, English, John, Vielkind, Jeurgen, Horsman, Doug, Laskin, Janessa J, Marra, Marco A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1952070/
https://www.ncbi.nlm.nih.gov/pubmed/17626639
http://dx.doi.org/10.1186/1471-2407-7-128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1952070/
https://www.ncbi.nlm.nih.gov/pubmed/17626639
http://dx.doi.org/10.1186/1471-2407-7-128

Ejemplares similares